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esponsibility of Xi'aAbstract The present work reports a simple, fast and sensitive microbiological assay applying the turbidimetric
method for the determination of ciproﬂoxacin hydrochloride (CIPRO HCl) in ophthalmic solutions.
The validation method yielded good results and included excellent linearity, precision, accuracy and speciﬁcity.
The bioassay is based on the inhibitory effect of CIPRO HCl upon the strain of Staphylococcus epidermidis
ATCC 12228 used as the test microorganism. The results were treated statistically by analysis of variance
(ANOVA) and were found to be linear (r¼0.9994, in the range of 14.0–56.0 mg/mL), precise (intraday RSD
%¼2.06; interday RSD%¼2.30) and accurate (recovery¼99.71%). The turbidimetric assay was compared to
the UV spectrophotometric and HPLC methods for the same drug. The turbidimetric bioassay described on this
paper for determination of ciproﬂoxacin hydrochloride in ophthalmic solution is an alternative to the
physicochemical methods disclosed in the literature and can be used in quality control routine.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Ciproﬂoxacin hydrochloride (CIPRO HCl), namely 1-cyclopropyl-
6-ﬂuoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic
acid hydrochloride (Fig. 1), is a second generation ﬂuoroquinolone
antimicrobial with a wide spectrum of activity against Gram-positive
and Gram-negative bacteria, including Pseudomonas aeruginosa [1].sity. Production and hosting by Else
7
33016960.
m.br (E.C.L. Cazedey)
n Jiaotong University.The mode of action of ﬂuoroquinolones involves interactions with
both DNA gyrase, the originally recognized drug target, and
topoisomerase IV, a related type II topoisomerase [2].
The drug is ofﬁcial in British Pharmacopoeia [3] presenting an
HPLC assay for CIPRO HCl tablets and ciproﬂoxacin lactate
intravenous infusion. In Brazilian Pharmacopoeia [4] three meth-
ods are proposed to determine CIPRO injection, CIPRO HCl
tablets and ophthalmic solution; an UV spectrophotometric, an
HPLC and a microbiological diffusion agar methods. The United
States Pharmacopoeia [5] describes an HPLC method for CIPRO
and CIPRO HCl assay in bulk, CIPRO injection, ophthalmic
ointment, ophthalmic solution and tablets.
Despite most methods presented in ofﬁcial compendia are
physicochemical assays, these methods do not represent the
potency of antimicrobials neither can predict the loss of activity.vier B.V. All rights reserved.
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Fig. 1. Chemical structure of ciproﬂoxacin hydrochloride.
Microbiological assay for ciproﬂoxacin hydrochloride 383Furthermore, the low cost and simple procedures of bioassays have
allowed them to become an alternative methodology for drug
potency assessment in pharmaceutical formulations.
The literature has reported microbiological assays by agar
diffusion method for determination of others ﬂuoroquinolones in
pharmaceutical formulations, such as norﬂoxacin [6], sparﬂoxacin
[7], oﬂoxacin [8], enroﬂoxacin [9], lomeﬂoxacin [10], gatiﬂoxacin
[11] and orbiﬂoxacin [12]. However, no microbiological assay
using turbidimetric method for the determination of quinolones has
been reported yet. This assay is faster than agar diffusion method
and presents easier management. The microbiological assay can
reveal subtle changes not demonstrable by chemical methods and
it gives the possibility to evaluate the potency of this substance,
which is very important for the analysis of antibiotics. Bioassay is
an ecological technique because it is not a residue or solvent
producer. Moreover, microbiological assay requires no specialized
equipment or toxic solvents [13].
In this paper, a novel, rapid, simple and sensitive turbidimetric
bioassay method is described for determination of CIPRO HCl in
ophthalmic solution as an alternative to the physicochemical
methods described in the literature.2. Materials and methods
2.1. Chemicals and instruments
CIPRO HCl reference standard (assigned purity 100%) was kindly
supplied by EMS Sigma Pharma Group (São Paulo, Brazil).
Pharmaceutical dosage form (ophthalmic solution) containing
CIPRO HCl was obtained commercially and claimed to contain
3.5 mg/mL of drug and boric acid, sodium citrate, dissodium
edetate (EDTA), benzalconium chloride and purity water as
excipients.
All chemicals and reagents used were of analytical grade. High
purity water was prepared using Millipore Milli-Q puriﬁcation
system (Millipore, Bedford, MA, USA). The absorbances were
carried out in spectrophotometer Beckman model DUs 530
(California, USA).
2.2. Microorganism and inoculum
The cultures of Staphylococcus epidermidis ATCC 12228 were
cultivated on Casoy agar and maintained in the freezer as stock.
The cultures were pealed to brain heart infusion (BHI) broth (24 h
before the assay) and kept at 3671 1C. A culture broth of 2572%
turbidity (transmittance) was obtained at 530 nm, using a suitable
spectrophotometer and a 10 mm diameter test tube as absorption
cells against BHI broth as blank.2.3. Preparation of the standard solutions
Accurately weighed 100 mg of CIPRO HCl reference standard
was transferred to a 100 mL volumetric ﬂask and dissolved in
water (ﬁnal concentration of 1000 mg/mL). Aliquots of this
solution were diluted in water at concentrations of 14.0, 28.0
and 56.0 mg/mL, which were used in the assay.
2.4. Preparation of the sample solutions
Aliquots (40, 80 and 160 mL) of CIPRO HCl ophthalmic solution
(3500 mg/mL) were transferred volumetrically into 10 mL volu-
metric ﬂasks and added water to give a ﬁnal concentrations of
14.0, 28.0 and 56.0 mg/mL.
2.5. Turbidimetric assay
1.0 mL of the inoculated BHI broth was added in tubes containing
10.0 mL of sterile BHI broth. Aliquots of 200 mL of CIPRO HCl
reference standard and sample solutions were added in the respective
tubes. Twenty tubes were used to carried out parallel lines 3 3
design, three tubes for each concentration of standard and sample,
one tube for positive control (broth and inoculum), without addition
CIPRO HCl and one for negative control (only broth).
After incubation at 3572 1C for 4 h in shaker incubator, the
bacteria growing was discontinuous through adding 0.5 mL of
12% formaldehyde aqueous solution. The absorbance was deter-
mined in each tube using a spectrophotometer at 530 nm employ-
ing the negative control as blank.
2.6. Calculation
The potency of CIPRO HCl in ophthalmic solution was calculated by
Hewitt equation [14]. The assay was statistically treated by the linear
parallel model and by linear regression analysis. Analysis of variance
(ANOVA) was also used to verify the validity of the method.
2.7. Method validation
The method was appropriately validated by determination of the
following parameters: linearity, precision, accuracy, speciﬁcity and
robustness.
2.7.1. Linearity
The calibration curve was obtained with three doses of the reference
standard. The linearity was evaluated by linear regression analysis,
which was calculated by the least squares regression method.
2.7.2. Precision
The precision of the assay was determined by repeatability (intra-
assay) and intermediate precision (inter-assay). Repeatability was
evaluated by assaying the samples in the same concentration and
same day. The intermediate precision was studied by comparing
the assays on three different days. The results were expressed in
relative standard deviation (RSD%).
2.7.3. Accuracy
The accuracy was determined by % recovery of known amounts of
CIPRO HCl reference standard added (4.5, 24.5 and 44.5 mg/mL)
to the samples at the beginning of the process. Aliquots of 30 mL
Table 1 Conditions tested to establish the parameters for
microbiological assay of ciproﬂoxacin hydrochloride.
Parameters Conditions
Microorganism Bacillus subtilis ATCC 9372
Micrococcus luteus ATCC 9341
Staphylococcus epidermidis
ATCC 12228
Escherichia coli ATCC 10536
Culture medium BHI broth
Casoy broth
Müeller–Hinton broth
Concentration
of inoculum (%)
4.0
8.0
10.0
Diluents Water
Phosphate buffer pH 8.0
Concentrations (μg/mL) 1.75, 3.5, 7.0
14.0, 28.0, 56.0
Table 2 Experimental values of absorbance for ciproﬂoxacin
hydrochloride reference solutions obtained by microbiological
assay—turbidimetric method.
Concentration
(μg/mL)
Range of reference
solutions absorbance
Mean absorbancea
7RSD (%)
14.0 0.478–0.482 0.48070.43
28.0 0.401–0.416 0.40871.85
56.0 0.340–0.347 0.34471.05
aMean of three assays.
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into 10 mL volumetric ﬂasks containing 45, 245 and 445 mL of
CIPRO HCl standard solution (1000 mg/mL). Then, distilled water
was added to make up to volume and give the ﬁnal concentrations
of 15.0, 35.0 and 55.0 mg/mL. These solutions were assayed and
the percentage recovery of added CIPRO HCl was calculated.
2.7.4. Speciﬁcity
The ability of the proposed method to determine CIPRO HCl in
the presence of the excipients was assessed by comparing the
results obtained in the bioassay with the whole sample against the
results from the standard solution. The Student's t-test and F-test
were performed to compare the ciproﬂoxacin standard and sample
absorption values.
2.7.5. Robustness
Robustness was determined by analyzing the same sample under a
variety of conditions. The considered factors were incubation time
and volume of the inoculated BHI broth. The variation of the mean
absorbance between the different assays was statistically analyzed
by ANOVA.
2.8. Comparison of methods
The results obtained in this study were compared with those by
HPLC method described previously [15] and the UV spectro-
phometric method also developed by the authors.
2.8.1. Chromatographic conditions
The HPLC method was performed isocratically using a mobile
phase consisting of 2.5% acetic acid solution, methanol and
acetonitrile (70:15:15; v/v/v). The wavelength of the UV detector
was set at 275 nm. A Symmetry Waters C18 column
(250 mm 4.6 mm i.d., 5 mm particle size) was used [15].
2.8.2. UV spectrophotometric conditions
The UV spectrophotometric method was performed on a UV–vis
Shimadzu, model UVmini-1240. CIPRO HCl was detected at
275 nm using 0.5 M hydrochloride acid as solvent.3. Results and discussion
The experimental conditions were adjusted to accurately determine
the performance of the assay. Some parameters were tested earlier
to establish the conditions described and it is shown in Table 1.
To develop and validate this bioassay a strain of Staphylococcus
epidermidis was found to be the appropriate microorganism test
allowing quantitation of CIPRO HCl.
The microbiological assay described in this work was per-
formed in 3 3 design (three doses of standard and three doses of
sample), according to British [3], Brazilian [4], The United States
[5] and European Pharmacopoeias [16]. The calculation procedure
usually assumes a direct relationship between the observed
absorbance and the logarithm of the applied dose. The correspond-
ing mean absorbance for reference solutions was 0.48070.0012
(RSD¼0.43) for lower dose, 0.40870.0044 (RSD¼1.85) for
medium dose and 0.34470.0021 (RSD¼1.05) for higher dose
and that for ophthalmic solution was 0.47670.0069 (RSD¼2.51),
0.40270.0038 (RSD¼1.63) and 0.33870.0033 (RSD¼1.71) forconcentrations of 14.0, 28.0 and 56.0 mg/mL, respectively
(Table 2).
The calibration curves for CIPRO HCl were constructed by
plotting log concentrations (mg/mL) versus absorbance and
showed good linearity between 14.0 and 56.0 mg/mL concentration
range. The representative linear equation for CIPRO HCl was y¼
−0.0983 Ln(x)+0.7385, where x is log dose and y is absorbance.
The correlation coefﬁcient (r) was 0.9994. There was no deviation
from parallelism and linearity in our results (po0.05). The
precision and accuracy of the assay were also demonstrated. The
results obtained on different days (intermediate precision/inter-
assay) showed a relative standard deviation of 2.30% and those on
the same day (repeatability/intra-assay) showed a mean RSD of
2.06%. The accuracy was 99.71% (Table 3). The applicability
of this method was tested and the value obtained was 102.27% of
drug in the ophthalmic solutions.
In order to assess the robustness, some parameters were
modiﬁed from the normal conditions: incubation time (from 4 h
to 3 h 30 min and 4 h 30 min) and volume of the inoculated BHI
broth (from 10 mL to 9.8 and 10.2 mL). The Student's t-values
obtained showed that the method is robust to the parameter volume
of the inoculated BHI broth, but not for the incubation time, thus it
is established the need of exacts 4 h of incubation test.
Table 3 Experimental values obtained in the recovery test for ciproﬂoxacin hydrochloride in ophthalmic solutions by turbidimetric
method.
Sample concentrations (μg/mL) Concentration of added
standard (μg/mL)
Concentration of found
standard (μg/mL)
Percentage recoverya Mean percentage recovery7RSD
15.0 4.5 4.49 99.72 99.7171.52
35.0 24.5 24.06 98.19
55.0 44.5 45.05 101.23
aEach value is the mean of 3 determinations.
Table 4 Assay results of ciproﬂoxacin hydrochloride by
three different methods.
Day HPLC (%) UV (%) Microbiological (%)
1 107.09 101.34 99.96
2 101.01 99.35 106.22
3 101.64 99.67 100.63
Mean7
RSD%
103.2573.24 99.7971.39 102.2773.36
Microbiological assay for ciproﬂoxacin hydrochloride 385The data obtained in the analysis of CIPRO HCl in ophthalmic
solution using the microbiological assay were compared with
declared amounts and with those obtained by HPLC and UV
spectrophotometry methods (Table 4). Analysis of variance indi-
cated no signiﬁcant differences between these methods (po0.05).
The development and validation of analytical methods for the
determination of drugs has received considerable attention in
recent years because of their importance in pharmaceutical
analysis. A turbidimetric microbiological assay was proposed as
a rapid, simple and suitable method for the determination of
CIPRO HCl in ophthalmic solution.
The potency of an antibiotic may be demonstrated under
suitable conditions by comparing the inhibition of growth of
sensitive microorganisms produced by known concentrations of
the antibiotic to be examined and a reference standard [5].
According to British [3], Brazilian [4], The United States [5]
and European [16] Pharmacopoeias when a parallel-line model is
chosen the two log dose–response lines of the preparations to be
examined as well as the reference preparation must be parallel and
they must be linear over the range of doses used in the calculation.
These conditions must be veriﬁed by validity tests for a given
probability, usually p¼0.05. The assays were validated by means
of the analysis of variance, as described in these ofﬁcial codes.
Precision is usually expressed as the variance, relative standard
deviation (RSD%) of a series of measurements. The accuracy is
shown by the percentage of recovery. The data obtained in this
study conﬁrm the precision and accuracy of the turbidimetric
bioassay developed.
The results of analysis of the commercial colirium and the
recovery study suggested that there is no interference from any
excipients, which are present in pharmaceutical samples. Further-
more, the Student's t-values and F-tests values calculated for assay,
0.98 and 1.55, respectively, are below tabulated values (n¼6). The
tabulated values of t and F at 95% conﬁdence limit are t¼2.18 and
F¼4.28. These results showed that the microbiological assay was
speciﬁc and the impurities did not interfere in the capacity of the
method to assess the analyte.It was also considered necessary to evaluate small variations in
the analytical conditions. Thus, the method was robust for all
parameters, except by the incubation time, thereby it is established
the need to observance this factor.
The quantiﬁcation of antibiotic components by chemical
methods such as HPLC and UV spectrophotometry, although
precise, cannot provide a true indication of biological activity.
Attempts to correlate antibiotic bioassay results with those from
chemical methods have proved disappointing.
Although the biological assays have a high variability, the
analysis of the obtained results demonstrated that the proposed
method might be very useful for determination of this drug in
pharmaceutical dosage forms, being an acceptable alternative
method for the CIPRO HCl quality control routine.4. Conclusions
The microbiological turbidimetric assay validated for determina-
tion of CIPRO HCl in ophthalmic solution demonstrated simpli-
city, linearity, precision, speciﬁcity and accuracy. Moreover,
bioassay requires not specialized equipment and it is rapid
execution, being an acceptable alternative method for the CIPRO
HCl quality control routine.Acknowledgments
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